Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 26, 2018January 26, 2018

CRISPR Gene Editing Technique Featured in Upcoming Myeloma Immunotherapy Trial

News

A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the University of Pennsylvania. The small ... Read more

January 19, 2018January 19, 2018

First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma

News

The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple myeloma, the therapy’s developer, Poseida ... Read more

January 12, 2018January 12, 2018

Multiple Myeloma Patients Remain On Treatment Far Less than in Clinical Trials, Study Finds

News

Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical trials, a study found. ... Read more

January 10, 2018January 10, 2018

Empliciti Improves Response to Combo Treatment in Newly Diagnosed Myeloma Patients, Study Finds

News

Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone, a study from Japan demonstrates. The treatment ... Read more

December 22, 2017

BioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for Transplant

News

BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells from bone marrow before a stem ... Read more

December 13, 2017

Weighing Myeloma Cells Could Predict Treatment Responses, MIT Study Shows

News

Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could help doctors choose the right ... Read more

December 11, 2017December 11, 2017

First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment

News

The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma — Breakthrough Therapy Designation. Regulators at the ... Read more

December 8, 2017December 8, 2017

FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns

News

The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial hold in September 2017, ... Read more

November 17, 2017

Poseida Developing CAR T-cells to Replace Risky Stem Cell Transplant Pre-treatments

News

Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood cancer patient receives a stem cell transplant. This approach is ... Read more

November 15, 2017November 15, 2017

Janssen to Share Updates from Darzalex Studies at Hematology Meeting in Atlanta

News

Janssen plans to share new data from Phase 3 trials of Darzalex (daratumumab) for multiple myeloma at the 59th American Society of Hematology (ASH) Annual Meeting, scheduled for Dec. 9-12 in ... Read more